SORD
SORD neuropathy is an inherited neuropathy caused by variants in both copies of the SORD gene, which leave the body unable to break down sorbitol. It is often grouped with recessive CMT2 or dHMN. More in the glossary
-

·
Who Decides What Counts as CMT?
No single body owns the word CMT. Here is where the edge cases sit, who decides, how they decide, and how cmt.blog handles it.
-

·
Faster, Less Predictable: What the FDA’s Turbulent Years Mean for CMT
The FDA has promised faster, more flexible rare disease approvals, but rejections, reversals, leadership churn, and pressure on research funding have made it less predictable. What that means for CMT patients and researchers.
-

·
Three “Treatable CMT” Stories, and What the Market Taught Us
Three heavily publicized CMT treatments of 2019–2023 (govorestat, PXT3003, and Engensis) all ended without a CMT approval, and the way they ended says a lot about how drug development treats rare neuropathies.
-

·
The “First Treatable CMT Disease” is Neither CMT Nor a Disease
CMT-related research may truly do away with CMT disease first by eliminating or updating how naming and classification works in neurological pathology.
-

·
New Gene (PSAT1) Linked to Treatable CMT-like Outcomes
Two children with a CMT-like neuropathy caused by PSAT1 variants improved after taking serine, an early observation from one case report. It raises more questions about how CMT types are defined and diagnosed.
-

·
The “first treatable” form of CMT?
I wrote this brief article on the way the SORD gene works (or fails to work) for the Hereditary Neuropathy Foundation. SORD mutations cause “the most common autosomal recessive form of CMT2 (CMT2A1), autosomal recessive intermediate CMT (CMTRIA), and the overlapping category of distal hereditary motor neuropathy (dHMN).”
-

·
The Problem With Writing About CMT
I’ve been increasingly irritated lately by US-based CMT-related non-profit organizations that seem to compete with each other for donations — supposedly they drive research for “treatments and cures.” How well they actually do this relative to the padding of their own budgets is a good question I might take up down the line, but you…
-

·
A New Genetic Cause of a Previously Unknown Subtype of CMT2
Published in Nature Genetics last month, the INC group’s findings are a big deal, and there is a really cool story from the University of Miami’s Miller School of Medicine about how the research team came together.
-

·
Second Phase 3 Clinical Trial for CMT1A “Pleodrug”
In 2020, after the setback of a second phase 3 trial, Pharnext’s PXT3003 looked promising in people with CMT1A. Updated in 2026: that trial failed to improve disability, and Pharnext was liquidated.
